Where things stand
We'll tell you exactly what we can — and can't — prescribe.
Peptide therapy exists in a regulatory environment that's changing fast. We think you deserve a clear picture, not a marketing pitch.
Available now
Through licensed 503A compounding pharmacies.
Sermorelin
A GHRH analog with prior FDA approval. Signals your pituitary to produce its own growth hormone rather than replacing it directly, which means your body's natural feedback loops stay intact. Used for recovery, sleep quality, body composition, and aging-related GH decline.
NAD+
On the FDA's 503A approved compounding list. Central to mitochondrial function, cellular energy production, and DNA repair. Declining levels are one of the more consistent biomarkers of aging. IM and subcutaneous delivery available depending on your protocol.
Tesamorelin
FDA-approved GHRH analog. The most studied growth-hormone secretagogue in clinical literature. Documented effects on visceral fat reduction and metabolic markers.
PT-141 (Bremelanotide)
FDA-approved. Works upstream of the vascular system — acts on melanocortin receptors in the brain rather than blood flow. Used for sexual dysfunction in both men and women.
On our radar
Currently restricted. Reclassification pending.
The following compounds are currently restricted from 503A compounding under FDA Category 2 designation. HHS has publicly signaled intent to reclassify several of them. Formal publication is pending. We do not prescribe any of these today.
- BPC-157 — body protective compound; tissue repair, gut health, systemic healing.
- CJC-1295 / Ipamorelin — growth-hormone secretagogue stack.
- TB-500 (Thymosin Beta-4) — soft-tissue and cardiovascular repair.
- Thymosin Alpha-1 — immune modulation.
- AOD-9604 — modified GH fragment studied for fat metabolism.
- And several others on the Category 2 list under FDA review.
When reclassification lands, we move fast — through licensed providers, from tested pharmacies, with proper clinical oversight. Until then we do not prescribe these compounds, full stop, and we'd encourage you to be cautious about any provider who claims they will.
Where we draw a hard line
Compounds we won't prescribe — even if asked.
Some compounds aren't on our list and won't be, regardless of how the regulatory environment shifts. Two categories worth being explicit about:
- Active investigational drugs. Compounds still in active clinical trials with brand-name drug sponsors. The legal exposure for prescribing or compounding these outside trial protocols is unacceptable, and the safety data isn't in yet.
- Compounds requiring in-person evaluation. Some peptide protocols require physical exam, longitudinal lab monitoring, and in-person dose titration that telehealth cannot responsibly provide. We won't pretend otherwise. Your provider will flag these and refer you to in-person care if needed.